Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Cancer Female × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 96 Neoplasms 11 Neoplasm Metastasis 8 Sarcoma 6 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Melanoma 5 Colorectal Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lung Neoplasms 4 Leukemia, Myeloid, Acute 4 Multiple Myeloma 3 Liposarcoma 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Breast Diseases 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasm, Residual 2 Lymphoma, Non-Hodgkin 2 Inflammation 2 Head and Neck Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Esophageal Squamous Cell Carcinoma 2 Chordoma 2

Interventions

Tamoxifen 3 pyrotinib 2 abemaciclib 2 Metformin 2 Exercise 2 Cyclophosphamide 2 Capecitabine 2 Bupivacaine 2 Aromatase Inhibitors 2 palbociclib 1 exemestane 1 durvalumab 1 darolutamide 1 Yoga 1 Waiting Lists 1 Vitamin D 1 Tumor Burden 1 Tretinoin 1 Trastuzumab 1 Tocopherols 1 Thioctic Acid 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Standard of Care 1 Sodium Chloride 1 Self-Help Groups 1 Saline Solution 1 Ropivacaine 1 Radiotherapy 1 Radiofrequency Ablation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03065621 2023-04-19

NeoRHEA

Jules Bordet Institute

Phase 2 Completed

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡